Major facilitator superfamily MfsA contributes to multidrug resistance in emerging nosocomial pathogen Stenotrophomonas maltophilia. Dulyayangkul P, Charoenlap N, Srijaruskul K, Mongkolsuk S, Vattanaviboon P. J Antimicrob Chemother. 2016 Oct;71(10):2990-1. doi: 10.1093/jac/dkw233. No abstract

28 Dec 2016
0

Major facilitator superfamily MfsA contributes to multidrug resistance in emerging nosocomial pathogen Stenotrophomonas maltophilia.
Dulyayangkul P, Charoenlap N, Srijaruskul K, Mongkolsuk S, Vattanaviboon P.
J Antimicrob Chemother. 2016 Oct;71(10):2990-1. doi: 10.1093/jac/dkw233. No abstract

Tags

Share this

Related Posts

Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial)

Recent Posts